Sophiris Bio Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sophiris Bio Inc.
US IPO Market In 2022 Even Underperformed Normal Years
INFOGRAPHIC: The number of biopharma offerings in 2022 was far below records set in 2020 and 2021, but also below more normal years of 2018 and 2019. The IPO class of 2022 eked out a positive average return, however.
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Deals In Depth: January 2023
Eight $1bn+ alliances were penned in January. Topping the list was a potential $4.4bn deal between Neurocrine Biosciences and Voyager Therapeutics to advance multiple gene therapies for the treatment of neurological diseases.
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Large Molecule
- Other Names / Subsidiaries
- Protox Therapeutics, Inc.
- Sophiris Bio, Inc.
- Sophiris Bio Corp., Sophiris Bio Holding Corp.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.